睾酮(Testosterone) - 药物靶点：AR_在研适应症：低睾酮水平，睾酮缺乏，性腺机能减退_专利_临床

概要

基本信息

药物类型

小分子化药

别名

17beta-hydroxy-4-androsten-3-one、4-androsten-17β-ol-3-one、Testosterone (JAN/USP)

+ [34]

靶点

AR

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

内分泌与代谢疾病肿瘤遗传病与畸形+ [1]

在研适应症

低睾酮水平睾酮缺乏性腺机能减退+ [2]

非在研适应症

阿尔茨海默症雄激素缺乏症雄激素不敏感综合征+ [33]

原研机构

AbbVie, Inc.

在研机构

秦皇岛紫竹药业有限公司

National Institute of Child Health & Human DevelopmentEndo Operations Ltd.

+ [5]

非在研机构

Bayer AG

AbbVie, Inc.

Eli Lilly & Co.

+ [18]

最高研发阶段批准上市

首次获批日期

美国 (1995-09-29),

性腺机能减退

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C19H28O2

InChIKeyMUMGGOZAMZWBJJ-DYKIIFRCSA-N

CAS号58-22-0

关联

449

项与睾酮相关的临床试验

NCT01894308

/ Not yet recruiting临床2期

A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine TDS-Testosterone 5% in Adult Male Subjects

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

开始日期2025-06-01

申办/合作机构

Transdermal Delivery Solutions Corp.

NCT06733350

/ Recruiting临床4期IIT

Investigating the Effect of Testosterone Replacement Therapy Among Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate cancer. Hypogonadal men have low testosterone associated with symptoms such as low libido and erectile problems. TRT can be used to treat hypogonadism by increasing testosterone levels, which may improve associated symptoms. TRT is often not used in men with prostate cancer due to concerns it may lead to the cancer growing or spreading. This may lead hypogonadal men to have a poor quality of life or to discontinue AS. TRT may improve treatment and quality of life outcomes in hypogonadal men with localized prostate cancer on active surveillance.

开始日期2025-01-15

申办/合作机构

Roswell Park Comprehensive Cancer Center

RBR-8xtsgvv

/ Not yet recruitingN/AIIT

Evaluation of Metabolic, Inflammatory, Cardiovascular and Endothelial Risk markers in transgender men on Testosterone therapy

开始日期2024-12-15

申办/合作机构-

100 项与睾酮相关的临床结果

登录后查看更多信息

100 项与睾酮相关的转化医学

登录后查看更多信息

100 项与睾酮相关的专利（医药）

登录后查看更多信息

116,145

项与睾酮相关的文献（医药）

2025-05-01·Journal of Environmental Sciences

The effects of 17β-trenbolone and bisphenol A on sexual behavior and social dominance via the hypothalamic-pituitary-gonadal axis in male mice

Article

作者: Sun, Minghe ; Luan, Jialu ; Zhao, Qili ; Zhang, Shuhui ; Feng, Xizeng ; Bai, Huijuan ; Sun, Mingzhu ; Zhao, Xin ; Yu, Qian ; Fu, Zhenhua ; Zuo, Xiang

17β-Trenbolone (17-TB) is well documented as an environmental endocrine disruptor in aquatic biological studies, but its effects on mammals remain poorly understood. Furthermore, 17-TB acts as a hormone with properties similar to testosterone, and the consequences of juvenile exposure on adult social behavior remain uncertain. Bisphenol A (BPA) acts as an estrogen-like hormone, compared to 17-TB. Three-week-old male Balb/c mice were exposed orally to 17-TB (100 µg/(kg·day)) and BPA (4 mg/(kg·day)) for 28 days. Assessments of social interactions and a three-chamber test showed that 17-TB increased virility in male mice, intensified both male and female sexual behavior, and attracted and accepted female mice. It also increased social dominance through tube tests in male mice and markedly activated the c-Fos⁺ immune response in the medial prefrontal cortex (mPFC) and basal amygdala (BLA). ELISA data showed that 17-TB and BPA exposure significantly affected serum gonadotropin-releasing hormone (GnRH), growth hormone (GH), estradiol (E2), and luteinizing hormone (LH) levels, as well as testicular lesions and androgen receptor (ARβ) and estrogen receptor (ERα) synthesis. Testicular transcriptomic analysis further confirmed that could disrupt steroid synthesis and linoleic acid-related biometabolic processes. These findings suggest the influence of 17-TB and BPA exposure on sexual behavior and fertility in male mice, possibly through modulation of the hypothalamic-pituitary-gonadal axis. This study provides insights relevant to human reproductive health and neuro-social behavioral research, and the potential risk of environmental disturbances should not be overlooked.

2025-04-01·DOMESTIC ANIMAL ENDOCRINOLOGY

Active immunization with a novel recombinant GnRH vaccine inhibits reproductive function in male goats

Article

作者: Zhu, Yanyun ; Li, Yunsheng ; Li, Jian ; Wu, Zhuoya ; Pan, Zhihao ; Liu, Xuelan ; Gong, Xinbao ; Di, Moyan ; Zhang, Wei ; Liu, Ya ; Fang, Fugui ; Guo, Shibao ; Li, Mengxian

Gonadotropin-releasing hormone (GnRH) vaccines have been widely used to effectively inhibit gonadal development and reproductive function. To improve the immunogenicity of GnRH, we developed and evaluated the effects of GnRH6-kisspeptin-CRM197 immunization on the reproductive function in male goats. Thirty 3-month-old male goats (n = 30) were randomly assigned to control, surgical, and immunized groups. The immunized group received a 2 mL injection of the GnRH6-kisspeptin-CRM197 with a booster administered four weeks later. The control group was administered a white oil adjuvant. Blood samples were collected at regular intervals, and at week 20, the animals were euthanized for tissue collection. Serum antibody titers and testosterone levels were measured using ELISA and CLIA, respectively. Testicular parameters and histology were evaluated. The mRNA levels of reproductive-related genes in the HPG axis were measured using RT-qPCR. The results showed that the immunized goats had significantly increased serum GnRH and kisspeptin antibodies (P < 0.05) but decreased testosterone concentrations (P < 0.05) compared to the control group. Testicular size and histology were significantly affected in the immunized group, with notable reductions in testicular weight and dimensions (P < 0.01), and evidence of vacuolar degeneration and suppressed sperm production. The mRNA levels of FSHβ and LHβ in the pituitary, as well as FSHR, LHR, 3βHSD, and 17βHSD in the testis, were significantly lower in the immunized group compared to controls (P < 0.05). These findings suggest that GnRH6-kisspeptin-CRM197 is a safe antigen and a promising immunocastration vaccine with enhanced efficacy.

2025-04-01·TISSUE & CELL

Elderberry diet improves sperm quality and histological parameters of testicular tissue in adult male rats exposed to methamphetamine

Article

作者: Moghaddam, Meysam Hassani ; Hasanzadeh, Maral ; Mofarahe, Zahra Shams ; Niakan, Zahra ; Sani, Mojtaba ; Khanjari, Ghazal ; Ezi, Samira ; Hemmatparast, Haleh ; Norouzian, Mohsen ; Beirami, Amirreza ; Aliaghaei, Abbas ; Raee, Pourya ; Fathi, Mobina ; Vakili, Kimia ; Hajibeygi, Ramtin ; Amini, Nahal Babaeian ; Abdollahifar, Mohammad-Amin

Psychotropic stimulants like methamphetamine (METH) have an impact on the physiology, behavior, and psychology of human beings and can damage the reproductive and neuroendocrine systems in them. These deleterious impacts include a temporary drop in the relative weight of the testis along with adverse effects on spermatogenesis. Sambucus nigra, also known as elderberry (EB) or sweet elder, is a source of bioactive compounds that has drawn growing attention for its potential beneficial impact in preventing and treating several diseases. In this experimental research, 36 adult male rats were classified into three groups: (1) control, (2) METH, and (3) METH receiving the EB diet. The rats were injected with METH at a dose of 20 mg/kg for 28 days during treatment with the EB diet. Then, the rats were euthanized, and their sperm samples were collected for sperm parameters analysis. Afterward, the testis samples were taken for histopathological experimentations, immunohistochemistry against TNF-α and caspase-3, and serum testosterone levels. Our findings indicated largely improved sperm and stereological parameters, like spermatogonia, primary spermatocyte, round spermatid, and Leydig cells, and an increased serum testosterone level in the METH group receiving the EB diet compared to the other METH group. The results also revealed a significantly decreased TNF-α and caspase-3 expression in the METH+EB group compared to the METH group. In conclusion, the EB diet is regarded as an alternative treatment for improving the spermatogenesis process in reproductive toxicity induced by METH exposure.

244

项与睾酮相关的新闻（医药）

2025-02-06

·PRNewswire

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

SALT LAKE CITY, Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression (PPD) treatment. As previously disclosed, the Company was scheduled to meet with the U.S. Food and Drug Administration (FDA or the Division) in Q1 2025 to discuss the NDA submission package of LPCN 1154. Following the meeting, the Company was advised that the Division believes, in addition to the previously completed PK bridge data, an efficacy and safety study of oral LPCN 1154 in the target population will be required for 505(b)(2) NDA submission. Lipocine remains committed to advancing a rapid relief treatment for postpartum depression. Based on the guidance received and observed comparable exposure of LPCN 1154 and the reference drug in the completed PK bridge study, Lipocine is planning next steps toward the execution of a phase 3 safety and efficacy study. "The regulatory guidance regarding a safety and efficacy study provides an opportunity to generate safety and depression symptom relief data with LPCN 1154, which we believe will be beneficial for potential inclusion in product labeling and eligibility for clinical investigation exclusivity for a 48-hour, oral treatment option," said Mahesh Patel, CEO of Lipocine. "Furthermore," Dr. Patel added, "the planned study will investigate the potential of oral brexanolone to treat anxiety disorders, representing another attractive commercial opportunity with a high unmet need." About LPCN 1154 LPCN 1154 is an oral formulation of brexanolone in development targeted for administration resulting in rapid relief of PPD. Brexanolone is a bioidentical to naturally occurring neuroactive steroid, allopregnanolone, a positive allosteric modulator of y-aminobutyric acid (GABAA) receptor. LPCN 1154 is expected to have characteristics that could be particularly appealing to patients with severe PPD, acutely elevated suicide risk, and in whom rapid improvement is a priority while presenting no significant risk of adverse reactions to breastfed infants from exposure to brexanolone. About Postpartum Depression and Unmet Needs PPD is a major depressive disorder with onset either during pregnancy or within four weeks of delivery, with symptoms persisting up to 12 months after childbirth. Hormonal changes leading to GABA dysfunction are common in depression and pregnancy. Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide. Results from a recent survey (Truist Securities Research, January 2024) show that obstetricians believe approximately 20-40% of their patients may suffer from PPD. Further, obstetricians are comfortable making a diagnosis and prescribing antidepressants for PPD. Traditional antidepressants, not approved for PPD, have slow onset of action, side effects such as weight gain, and do not demonstrate adequate remission post-acute treatment. About Lipocine Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit . Forward-Looking Statements This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product candidates and related clinical trials, our development of our product candidates and related efforts with the FDA, including with respect to LPCN 1154, our current intention to conduct a safety and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, the timing of our submission of a NDA with the FDA for LPCN 1154, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at . Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law. SOURCE Lipocine Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准申请上市

2025-01-30

·MedCity News

Telehealth Clinic Hone Health Secures $33M, Acquires Home Health Company - MedCity News

Hone Health, a telehealth clinic for preventive longevity care, announced Tuesday that it has raised $33 million in Series A funding, which it is using to acquire home health company ivee. New York City-based Hone Health is a direct-to-consumer company that offers access to medications, lifestyle interventions, doctor consultations and community support starting at $129 a month. Consumers start with an analysis, including undergoing a 50-biomarker blood test and providing personal health history. They then have a video consultation with a physician to create a personalized plan for medications, supplements and lifestyle interventions. Some of its treatments include testosterone, vitamin B12 and naltrexone for weight loss. After that, they have quarterly biomarker tests and physician check-ins. The Series A round included participation from Tribe Capital, PIF, Republic Capital, Vibe VC, Humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs and Agent Capital. In total, Hone Health has raised $39 million. Sponsored Post The Funding Model for Cancer Innovation is Broken — We Can Fix It Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches. By Eve McDavid - CEO of Mission-Driven Tech “Hone Health has quickly emerged as a leader in men’s health, prioritizing patient safety and delivering a unique, comprehensive solution that addresses critical market needs,” said Ted Maidenberg, partner from Tribe Ventures, in a statement. “We are excited to support their next phase of growth as they continue to expand their footprint into longevity and holistic healthcare.” With the financing, Hone Health acquired ivee to introduce home health services to its customers. Ivee’s services include IV therapy and phlebotomy. “This expansion enhances patient access to high-quality, personalized treatment while underscoring Hone Health’s commitment to safety and innovation in healthcare,” said Saad Alam, CEO and co-founder of the company, in an email. The idea for Hone Health was born out of Alam’s own experiences in the healthcare system. Exclusive Improving the Healthcare Financial Experience to Help Care Flow Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all. By Stephanie Baum “When I turned 35, I started to experience symptoms of weight gain, loss of mental acuity and stamina, and a little bit of depression,” Alam said. “I kicked around the healthcare system for about a year, and no one could give me a really thorough answer. And then I met a group of hormone optimization regenerative physicians, and they told me that I was suffering from low testosterone. When I started to look at how large the problem was, it really took me back because there were hormonal imbalances not only in men, but also women.” Hone Health isn’t the only company focused on preventive health. Others include Malla and Parsley Health. When asked about the company’s goals ahead, Alam said it’s to scale the men’s and women’s businesses “dramatically.” Hone Health also hopes to conduct clinical trials on how well the business works. In addition, it aims to get to $100 million in recurring revenue in a “sustainable manner.” Picture: Feodora Chiosea, Getty Images

并购

2025-01-15

·Endpoints

DEA issues proposed rule to permanently expand online prescribing of controlled substances

The Drug Enforcement Administration on Wednesday issued a long-awaited proposed rule that would create a permanent process for clinicians to more easily prescribe controlled drugs online. The proposal would create a special registration process allowing telehealth doctors and mid-level practitioners to prescribe potentially addictive controlled substances without seeing a patient in person first, as federal law typically requires. Prescribing online without an initial in-person evaluation has been permitted by the DEA since the start of the Covid-19 public health emergency, thanks to several temporary extensions. A number of venture-backed telehealth companies grew rapidly as a result. Most recently, in November, the agency extended this flexibility until the end of 2025, after industry groups sounded the alarm that patients were poised to lose access to needed treatments. The proposed rule would essentially set that flexibility in stone for certain clinicians and add new requirements the DEA says are meant to expand access to care while allowing the agency better oversight. But some industry groups representing health systems, telehealth companies and other organizations that provide online care said the proposed rule may be too restrictive. In a statement, Kyle Zebley, senior vice president of public policy for the American Telemedicine Association, said that the proposed rule looks to contain “elements that represent significant operational challenges.” “All stakeholders need time to carefully review this important proposal, which appears to incorporate valuable elements and other potentially unworkable restrictions that focus on maintaining compliance with patient verification, electronic recordkeeping, and ongoing monitoring,” Zebley said. Meanwhile, the Alliance for Connected Care said it’s concerned that the proposal places limits on what portion of patient care can be offered through telemedicine and the geographies in which telemedicine can be offered. Comments on the rule are due in 60 days. Separately, the DEA and several other federal agencies finalized a rule Wednesday that allows DEA-registered clinicians to prescribe a six-month supply of buprenorphine, a controlled drug used to treat opioid use disorder, without seeing the patient in person. Those clinicians could write the buprenorphine prescription without having a special registration. Notably, the proposed rule discusses the challenges and risks associated with the recent rise of direct-to-consumer, prescription-writing telemedicine platforms. It proposes requiring companies that act as intermediaries in dispensing controlled substances to register with the DEA just like clinicians. “Although the telemedicine flexibilities during the PHE allowing practitioners to prescribe controlled substances without prior in-person medical evaluations were necessary to prevent lapses of care amid a global pandemic, it also facilitated the emergence of concerning business models engaged in the widespread diversion of controlled substances, taking advantage of the flexibilities established during the COVID-19 PHE,” the rule states. Though it doesn’t name any companies in the rule, the DEA last year fined mental health startup Cerebral for encouraging prescriptions of ADHD medications and other controlled drugs. The founder and head clinician of another startup, Done Global, were arrested and charged in June for inappropriate stimulant prescribing, according to the Justice Department. The proposed rule would create three types of special registrations: one for clinicians prescribing Schedule III through V controlled substances , which include anything from testosterone and ketamine to benzodiazepines like Xanax; another for specialized clinicians, such as psychiatrists and hospice care doctors, prescribing those and Schedule II drugs, such as stimulants and pain medication that have a higher risk of addiction and abuse; and one for telemedicine platforms dispensing Schedule II through V controlled substances. Each special registration would last for three years. In addition, the DEA would require clinicians to obtain from the agency another “state telemedicine registration” for every state in which they plan to prescribe controlled substances online. The proposed rule states that clinicians would also be subject to heightened requirements for prescriptions. For example, clinicians would need to check prescription drug monitoring programs (PDMPs) in all 50 states before writing a controlled substance prescription, though that requirement would go into effect three years after the rule is finalized. Before then, clinicians would be required to conduct a more limited PDMP check. The DEA also proposes placing limits on prescriptions for Schedule II controlled substances. It would require that the clinician with a special registration be physically located in the same state as the patient being treated. The proposed rule would also require that the clinician prescribe less than 50% of their average number of monthly prescriptions for Schedule II controlled substances through telemedicine. “Limiting the proportion of Schedule II prescriptions issued through telemedicine would help to manage the risks associated with the prescribing of Schedule II controlled substances by ensuring that a significant portion of these prescriptions are issued following in-person medical evaluations, which can provide a more comprehensive assessment of the patient’s medical history and condition than can be done remotely,” the proposed rule states. (This story is from our Health Tech newsletter. If you’d like to sign up, just click here. )

100 项与睾酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00075	睾酮	G03BA03	DB00624

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
继发性睾丸衰竭	美国	Endo Operations Ltd.	2010-12-29
心理性性功能障碍	欧盟	Teva NI Ltd.	2006-07-28
心理性性功能障碍	欧盟	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	冰岛	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	冰岛	Teva NI Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Teva NI Ltd.	2006-07-28
心理性性功能障碍	挪威	Teva NI Ltd.	2006-07-28
心理性性功能障碍	挪威	Warner Chilcott Ltd.	2006-07-28
低睾酮水平	美国	Endo Operations Ltd.	2002-10-31
睾酮缺乏	澳大利亚	Teva Pharmaceuticals Australia Pty Ltd	2002-04-10
性腺机能减退	美国	AbbVie, Inc.	1995-09-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性睾丸发育不全综合征	临床3期	美国	Amneal Intermediate, Inc.	2014-03-01
关节痛	临床3期	美国	National Cancer Institute	2013-09-10
关节痛	临床3期	波多黎各	National Cancer Institute	2013-09-10
乳腺癌	临床3期	美国	National Cancer Institute	2013-09-10
乳腺癌	临床3期	波多黎各	National Cancer Institute	2013-09-10
潮热	临床3期	美国	National Cancer Institute	2013-09-10
潮热	临床3期	波多黎各	National Cancer Institute	2013-09-10
肌肉骨骼畸形	临床3期	美国	National Cancer Institute	2013-09-10
肌肉骨骼畸形	临床3期	波多黎各	National Cancer Institute	2013-09-10
阿尔茨海默症	临床3期	美国	Solvay Pharmaceuticals, Inc.	2009-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02432261 (CTgov)	临床1期	-	44	Nestorone® /testosterone gel (Group 1)	糧衊觸窪獵餘鑰築襯廠(獵獵鑰廠艱醖廠選網鹽) = 積衊憲廠窪憲選簾觸糧壓願獵淵獵膚餘積鑰觸 (構糧觸鑰積繭築構蓋蓋, 壓製積選鬱壓糧鑰鬱廠 ~ 蓋簾餘襯醖衊觸醖製遞) 更多	-	2025-02-13
				Testosterone only gel (Group 2)	糧衊觸窪獵餘鑰築襯廠(獵獵鑰廠艱醖廠選網鹽) = 遞網淵構齋衊範鬱簾鹽壓願獵淵獵膚餘積鑰觸 (構糧觸鑰積繭築構蓋蓋, 淵構艱蓋簾鬱壓衊繭鏇 ~ 獵蓋餘餘壓餘鏇憲醖窪) 更多
NCT02938923 (STEP-HI, CTgov)	临床3期	髋部骨折 \| 肌肉减少症	129	Testosterone+Supervised exercise training (Exercise + Testosterone (EX + T))	積遞願淵選壓製醖範窪(廠獵鹹顧鑰餘鑰衊簾鬱) = 鹹窪觸襯膚衊積膚襯餘壓製築構顧鑰網積糧選 (獵衊遞蓋鹹襯獵艱簾築, 觸蓋簾襯簾選衊鑰淵憲 ~ 衊範鏇簾餘遞鬱艱夢構) 更多	-	2025-02-04
				Supervised exercise training (Exercise + Placebo (EX + P))	積遞願淵選壓製醖範窪(廠獵鹹顧鑰餘鑰衊簾鬱) = 憲衊簾艱夢鹽鬱艱齋艱壓製築構顧鑰網積糧選 (獵衊遞蓋鹹襯獵艱簾築, 鏇淵廠鬱憲鏇構觸憲齋 ~ 鹹簾範淵製窪製壓繭鹽) 更多
UEGW2024	N/A	原发性恶性肝肿瘤 testosterone \| estradiol \| tumor necrosis factor receptor superfamily member 9 (TNFRS9) ... 更多	-	TESTOSTERONE (Estradiol levels)	糧艱積網醖製顧簾窪鹹(夢淵鬱遞願鑰餘廠觸淵) = 觸糧製鹹鬱艱淵鬱壓廠齋淵襯齋憲鑰鏇鹽鏇構 (壓積構製窪糧鬱壓膚鏇 ) 更多	积极	2024-10-13
NCT05781685 (CTgov)	早期临床1期	急性疼痛	20	Testosterone+Placebo Syrup (Testosterone)	糧鑰餘獵簾鬱襯膚製繭(蓋齋繭鏇夢窪製淵夢廠) = 鏇廠簾網齋膚窪窪遞淵糧齋憲糧膚選鬱鏇憲願 (窪願簾鏇壓壓願網鬱憲, 網艱膚繭襯製鹹夢壓積 ~ 醖構壓積範廠夢鏇選積) 更多	-	2024-08-05
				Testosterone+Placebo Syrup (Placebo)	糧鑰餘獵簾鬱襯膚製繭(蓋齋繭鏇夢窪製淵夢廠) = 獵製齋繭簾膚襯築壓觸糧齋憲糧膚選鬱鏇憲願 (窪願簾鏇壓壓願網鬱憲, 夢廠觸簾鑰壓淵餘選餘 ~ 網鹽範壓遞鹽襯築艱鬱) 更多
ADA2024	N/A	肥胖	-	Testosterone Replacement Therapy (TRT)	憲鑰選構膚窪蓋鹹繭願(鬱製範憲鏇遞夢簾襯餘) = 鑰鬱遞膚範築鹹鹹顧餘膚鹽糧憲顧構廠鹹艱顧 (遞鹽積構艱積餘膚淵糧 ) 更多	-	2024-06-14
Testosterone II (TSTII) (ENDO2024)	N/A	肾细胞癌 testosterone	-	Testosterone II (TSTII) Immunoassay (Atellica IM Testosterone II (TSTII) assay)	糧顧艱遞遞膚製積淵獵(網鏇糧壓襯鏇餘憲鏇範) = 夢簾襯簾膚遞鑰膚糧簾廠構淵餘鑰築構糧觸構 (壓獵窪鹹餘鬱夢衊鏇顧 )	-	2024-06-01
				Testosterone II (TSTII) Immunoassay (ADVIA Centaur Testosterone II (TSTII) assay)	糧顧艱遞遞膚製積淵獵(網鏇糧壓襯鏇餘憲鏇範) = 壓獵憲觸襯範夢鏇淵艱廠構淵餘鑰築構糧觸構 (壓獵窪鹹餘鬱夢衊鏇顧 )
Near Term Cardiometabolic Outcomes in Transgender Boys and Men (ENDO2024)	N/A	E2	51	Transgender Men on Testosterone Therapy	夢積鑰製範繭衊遞顧顧(糧鹽鹽鬱憲艱糧蓋鬱醖) = 壓簾艱鏇憲鏇鑰網壓壓窪鹹觸鹽餘鏇衊遞鏇糧 (遞構齋鏇齋衊窪顧鏇鏇 ) 更多	-	2024-06-01
Testosterone Modulation of Muscle Transcriptome Profile (ENDO2024)	N/A	性腺机能减退 \| 肥胖 early AM testosterone	83	Testosterone Replacement + Lifestyle Therapy	壓膚餘鹹齋蓋鹽遞鏇廠(夢鬱鏇遞艱鑰窪觸鹽鹹) = 構齋糧繭鏇選鑰艱觸遞選憲夢淵襯遞鹹積鹽醖 (獵餘築範獵觸製築願膚 ) 更多	积极	2024-06-01
				Placebo + Lifestyle Therapy	壓膚餘鹹齋蓋鹽遞鏇廠(夢鬱鏇遞艱鑰窪觸鹽鹹) = 範網廠願廠積選鏇築構選憲夢淵襯遞鹹積鹽醖 (獵餘築範獵觸製築願膚 ) 更多
ATS2024	N/A	急性肺损伤	-	Anabolic Testosterone Isocaproate	醖襯鏇醖廠衊膚蓋膚糧(艱選鑰鬱鏇積襯觸鏇獵) = Our patient is a 46-year-old smoker who presented with two days of progressively dyspnea preceded by two weeks of cough. His history was significant for polysubstance use disorder. In the emergency department, he was found to be hypoxic to 60% with diffuse crackles and expiratory wheezes on exam, so he was given a dose of systemic steroids and started nebulizers. Chest radiograph and chest CT scan (figure 1) showed diffuse bilateral ground glass opacities. His respiratory status deteriorated rapidly, and he was intubated, then he was ultimately admitted to the MICU for acute hypoxemic respiratory failure. All infectious work-up including sputum culture and rapid respiratory pathogen PCR were negative. Over the next three days, he continued to have higher oxygen requirements, so empiric steroids were given then flexible bronchoscopy was performed with BAL demonstrating eosinophils of 14%, and lymphocytes of 3%. BAL bacterial and fungal cultures were negative. He was started on IV methylprednisolone, responded very well and after 3 days he was extubated. Following extubation, he reported using non-prescribed anabolic testosterone isocaproate for bodybuilding over the past several months and had three similar presentations with respiratory distress with chest CT also showing bilateral ground glass opacities and negative infectious workup. In all of them, he exhibited clinical improvement following each of these presentations with normal chest radiographs in between. He was followed in pulmonary clinic and was advised to stop using anabolic steroids with no recurrence to date. 衊糧顧簾遞餘憲齋蓋範 (餘蓋觸觸壓願獵網廠構 )	-	2024-05-19
ISN WCN2024	N/A	梗塞	-	Rivaroxaban 15mg/day	壓鑰膚鏇遞鹽艱齋糧鹽(製鏇廠鹽鑰艱願窪鬱鏇) = 膚鑰願製願簾窪鑰淵鹹選構獵顧築鬱範衊鬱糧 (積願衊簾淵鏇醖襯範壓 )	-	2024-04-01